abm | Stable Mgat2 Knockout K16 CHO Cell Line | T6008

(No reviews yet) Write a Review
SKU:
T6008
Availability:
5 to 7 Days Shipment
Size:
10⁶ cells/1.0 ml
zł25,538.76

 Select your currency from the header

Description

abm | Stable Mgat2 Knockout K16 CHO Cell Line | T6008

Using CRISPR technology Mgat2 was silenced from the K16 CHO cells to generate a glycosylation mutant cell line which expresses hybrid type N-glycans. Mgat2 synthesizes the Mannosyl (Alpha-1,6-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase enzyme (GlcNAcT-II) which plays a key role in the development of mammals in which carbohydrate-dependent interactions facilitate cell signaling, adhesion and migration. Carbohydrate-carbohydrate interaction by the hybrid type N-glycans has been shown to induce faster cell-cell adhesion and cell migration. Further research and discovery on the functions of N-glycans can be assessed with the Stable Mgat2 Knockout K16 CHO Cell Line.

Biosafety:

II

Organism:

Hamster

Source Organ:

Ovary

Growth Properties:

Adherent

Morphology:

Polygonal

Clones:

N/A

Passage Number:

N/A

Population Doner:

N/A

Seeding Density:

Thaw entire contents into an appropriate T25 flask as specified in the Propagation instructions.

Markers:

E-cadherin

Applications:

For Research Use Only

Doner Gender:

N/A

Donor Ethnicity:

N/A

Knockdown Method:

Mgat2 (UDP-N-acetylglucosamine:-6-D-mannoside 1,2-N-acetylglucosaminyltransferase II) silenced through C residue inserted after the 22nd nucleotide residue causing frameshift mutation

Induction:

N/A

Overexpression:

N/A

Freeze Thaw:

N/A

Propagation:

The base medium for this cell line is Prigrow VIII medium available at abm

Preservation:

N/A

Quality Control:

1) 4 µg/ml of puromycin (G264) was used for clonal selection; 2) Mgat2 silencing was confirmed by DNA sequencing of targeted genomic region; 3) E-cadherin was determined through the use of Western blot method

Tumorgenicn:

N/A

Shipping Conditions:

Dry Ice

Storage Contidions:

-180°C

View AllClose

0 Reviews

View AllClose